Nov 3, 2021 | biomarkers, health policy, innovation, oncology, precision medicine |
because we know that cancer can be highly variable from one person to the other, based on the changes at the molecular level, each patient, even those with the same diagnosis, have a unique set of changes that influence how a person will respond to therapy, or how...
